Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in newly diagnosed AML
NCT00893373Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- Mar 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Started Mar 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00893373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00893373.